Phospho-PTPN1 (S50) Antibody

What is Phospho-PTPN1 (S50) Antibody and what does it specifically detect?

Phospho-PTPN1 (S50) antibody specifically recognizes Protein Tyrosine Phosphatase 1B (PTP1B) only when phosphorylated at serine residue 50. This antibody is crucial for studying the post-translational regulation of PTP1B, a non-receptor type protein tyrosine phosphatase encoded by the PTPN1 gene . PTP1B functions as a regulator of endoplasmic reticulum unfolded protein response and mediates dephosphorylation of EIF2AK3/PERK, thereby inactivating its protein kinase activity . The antibody allows researchers to specifically detect the phosphorylated form without cross-reactivity to the unphosphorylated protein, enabling precise study of PTP1B's regulatory state.

Commercial Phospho-PTPN1 (S50) antibodies demonstrate varied species reactivity profiles:

This cross-species reactivity is due to the high conservation of the serine 50 phosphorylation site and surrounding amino acid sequence across mammalian species .

What are the optimal storage conditions for maintaining Phospho-PTPN1 (S50) antibody activity?

To maintain antibody activity and stability, researchers should follow these storage recommendations:

• Store at -20°C for long-term storage (up to one year from receipt)

• For frequent use over short periods (up to one month), store at 4°C

• Avoid repeated freeze-thaw cycles which can compromise antibody performance

• Most formulations contain 50% glycerol, allowing aliquots to be taken without complete thawing

The presence of stabilizers such as BSA (typically 0.5-1 mg/ml) and preservatives like sodium azide (0.02-0.05%) in the formulation helps maintain antibody integrity during storage .

What controls should be included when using Phospho-PTPN1 (S50) antibodies?

When designing experiments with Phospho-PTPN1 (S50) antibodies, these controls are essential:

• Positive control: Lysates from calyculin A-treated cells (e.g., A431 or Jurkat) where PTP1B phosphorylation is enhanced

• Negative controls:

  • Lambda phosphatase-treated samples to demonstrate phospho-specificity

  • Untreated cell lysates showing minimal or no phosphorylation

  • Blocking with the immunizing phosphopeptide to confirm specificity

• Validation controls:

  • Comparison between wild-type PTP1B and PTP1B-S50A mutant (non-phosphorylatable) expression systems

  • Parallel blots with total PTP1B antibody to normalize phosphorylation signals

These controls help verify antibody specificity and validate experimental findings related to PTP1B phosphorylation status.

How does phosphorylation at Serine 50 affect PTP1B function?

Phosphorylation at Serine 50 significantly impacts PTP1B's enzymatic activity and signaling functions:

Understanding this post-translational modification provides insight into the complex regulation of insulin signaling and potential therapeutic targets for metabolic disorders.

What treatments enhance PTP1B phosphorylation at Serine 50 in experimental systems?

Researchers can modulate PTP1B Ser-50 phosphorylation using these established methods:

• Pharmacological inducers:

  • Calyculin A treatment significantly enhances phosphorylation, producing a characteristic doublet in Western blots of treated cell lysates

  • Insulin stimulation increases phosphorylation of wild-type PTP1B through Akt activation

• Genetic approaches:

  • Cotransfection with constitutively active Akt causes robust phosphorylation of wild-type PTP1B both in the absence and presence of insulin

  • Expression of phosphomimetic mutants (S50D) to simulate constitutive phosphorylation

• Inhibition approaches:

  • Pretreatment with wortmannin (PI3K inhibitor) or cotransfection with dominant inhibitory Akt mutant blocks insulin-stimulated phosphorylation

These experimental manipulations allow researchers to study the functional consequences of Ser-50 phosphorylation in various cellular contexts.

How can researchers distinguish between effects of Serine 50 phosphorylation and other post-translational modifications of PTP1B?

Distinguishing between different post-translational modifications requires systematic experimental approaches:

• Site-directed mutagenesis:

  • Generate specific mutants at Ser-50 (S50A or S50D) while preserving other modification sites

  • Create combination mutants to assess interplay between modifications

• Modification-specific antibodies:

  • Use antibodies targeting different modifications (e.g., phospho-Ser-50, phospho-tyrosine residues Y66, Y152, Y153, or oxidized Cys-215)

  • Perform parallel Western blots with these antibodies on the same samples

• Mass spectrometry approaches:

  • Employ phosphopeptide mapping to identify all phosphorylation sites simultaneously

  • Use SILAC-MS for quantitative assessment of multiple modifications

• Functional assays with specific modulators:

  • Compare effects of Akt activators (affecting Ser-50) versus treatments causing oxidation (affecting Cys-215)

  • Assess differential sensitivity to phosphatase inhibitors versus reducing agents

These approaches help deconvolute the complex regulatory network controlling PTP1B activity through various post-translational modifications.

How can substrate trapping mutants be integrated with Phospho-PTPN1 (S50) antibodies in advanced signaling studies?

Substrate trapping mutants of PTP1B can be powerful tools when combined with phospho-specific antibodies:

• Substrate identification strategy:

  • Generate substrate trapping mutants (D181A-Y46F) that stabilize enzyme-substrate complexes

  • Perform co-immunoprecipitation with these mutants followed by Western blot using Phospho-PTPN1 (S50) antibodies to examine if phosphorylation status affects substrate binding

• Subcellular localization studies:

  • Create truncated versions lacking the ER-targeting domain (Δ406-435) that localize to the cytosol

  • Compare substrate binding profiles between full-length and truncated phosphorylated/non-phosphorylated PTP1B variants

• Quantitative proteomics integration:

  • Combine SILAC-MS with substrate trapping approaches to identify and directly compare substrates/binding partners

  • Use Phospho-PTPN1 (S50) antibodies to immunoprecipitate phosphorylated PTP1B from these complexes

This integrated approach provides a comprehensive view of how phosphorylation at Ser-50 modulates PTP1B's substrate specificity and signaling functions.

What methodological approaches can resolve contradictory findings regarding Serine 50 phosphorylation effects?

The literature shows contradictory findings regarding Ser-50 phosphorylation effects, where phosphorylation by Akt decreases activity while phosphorylation by CLK1/CLK2 increases activity . To resolve these contradictions:

• Standardized in vitro assays:

  • Develop consistent phosphatase activity assays using defined substrates

  • Compare activities of recombinant PTP1B phosphorylated by different kinases under identical conditions

• Context-dependent analysis:

  • Examine effects in different cell types and signaling contexts

  • Determine if additional co-factors or binding partners influence the outcome

• Structural biology approaches:

  • Utilize crystallography to analyze conformational changes induced by phosphorylation

  • Apply techniques like IADDAT (integration of absolute difference density above threshold) analysis to map detailed, longer-range effects of phosphorylation on conformational ensembles

• Temporal resolution studies:

  • Investigate whether the effects of phosphorylation are time-dependent

  • Employ kinetic analyses to determine if initial stimulation might be followed by inhibition

These methodological approaches can help reconcile seemingly contradictory findings and provide a more nuanced understanding of how Ser-50 phosphorylation regulates PTP1B function.

How does PTP1B phosphorylation at Serine 50 contribute to its dual roles in metabolism and oncogenesis?

PTP1B has intriguing dual functions as both a negative regulator of insulin/leptin signaling and a positive factor in tumorigenesis :

• Metabolic regulation:

  • Phosphorylation at Ser-50 by Akt impairs PTP1B's ability to dephosphorylate the insulin receptor, enhancing insulin signaling

  • This mechanism creates a positive feedback loop in insulin signaling, where insulin activation of Akt leads to PTP1B inhibition, which further enhances insulin receptor activity

• Cancer implications:

  • In breast cancer contexts, alterations in PTP1B phosphorylation status may affect its interactions with key signaling proteins

  • The role of PTP1B variants has been studied in relation to extreme phenotypes like persistent healthy thinness, with implications for metabolism and potentially cancer susceptibility

• Crosstalk regulation:

  • Phosphorylation at Ser-50 may differentially affect PTP1B's activity toward distinct substrates

  • In addition to insulin receptor, PTP1B regulates multiple pathways including EFNA5-EPHA3 signaling (cell reorganization) and MET (hepatocyte growth factor receptor)

Understanding how Ser-50 phosphorylation affects these diverse functions provides insight into PTP1B's role at the intersection of metabolism and oncogenesis, making it a particularly attractive therapeutic target for diabetes, obesity, and potentially breast cancer .

What are the most common technical challenges when working with Phospho-PTPN1 (S50) antibodies?

Researchers frequently encounter these challenges when working with Phospho-PTPN1 (S50) antibodies:

• Low signal strength:

  • Endogenous phosphorylation levels may be very low in unstimulated cells

  • Recommended solution: Treat cells with calyculin A or other phosphatase inhibitors before lysis

• Non-specific bands:

  • Multiple bands may appear due to cross-reactivity with related phosphatases

  • Recommended solution: Include appropriate blocking peptides and optimize antibody dilution

• Inconsistent results:

  • Phosphorylation levels may vary with cell density, passage number, and growth conditions

  • Recommended solution: Standardize cell culture conditions and include positive controls in each experiment

• Limited detection in certain tissues:

  • PTP1B expression varies across tissues, affecting phospho-specific detection

  • Recommended solution: Verify total PTP1B expression before attempting phospho-specific detection

• Antibody batch variation:

  • Different lots may show variation in specificity and sensitivity

  • Recommended solution: Validate each new lot against a reference standard

Addressing these challenges requires careful experimental design and appropriate controls to ensure reliable detection of phosphorylated PTP1B.

What is the recommended procedure for validating a new Phospho-PTPN1 (S50) antibody lot?

To ensure consistent research outcomes, validation of each new antibody lot should include:

• Western blot comparison:

  • Run side-by-side Western blots with previous and new lots using identical samples

  • Compare band patterns, intensity, and background levels

  • Test with both positive controls (calyculin A-treated cells) and negative controls (untreated cells)

• Phosphatase treatment control:

  • Treat duplicate samples with lambda phosphatase to confirm phospho-specificity

  • Signal should disappear or significantly decrease after phosphatase treatment

• Peptide competition assay:

  • Pre-incubate antibody with the immunizing phosphopeptide

  • Signal should be specifically blocked by the phosphopeptide but not by non-phosphorylated peptide

• Dilution optimization:

  • Test multiple dilutions to determine optimal working concentration

  • Compare signal-to-noise ratio across different applications (WB, IHC, ICC)

• Cross-reactivity assessment:

  • Test specificity using samples expressing PTP1B-S50A mutant

  • Evaluate potential cross-reactivity with other phospho-proteins in the same family

Thorough validation ensures experimental reproducibility and reliability of results obtained with Phospho-PTPN1 (S50) antibodies.